Genomic characterization of a cell-culture-adapted Korean human G9P[8] rotavirus, CAU05-202

Abstract

The human rotavirus G9 strain is the fifth most common rotavirus worldwide. A human rotavirus G9P[8] strain CAU05-202 was isolated from a young child with diarrhea using a cell culture system, and its major gene sequences were determined. Phylogenetic analysis of the VP7 gene revealed that CAU05-202 clustered into genetic lineage III-d and was most closely related to G9 rotaviruses from Turkey (strain GUH13) and Sri Lanka (strain 05SLC056 and 05SLC057). VP4 and NSP4 gene analysis showed that CAU05-202 belongs to the P[8]-3 lineage and genotype B, respectively. In addition, CAU05-202 has a long RNA electropherotype, supported by VP6 gene analysis, which is clearly associated with subgroup II specificity. Analysis of the G9 rotavirus strain CAU05-202 provides information concerning the genetic relationships among global rotavirus G9 strains, suggesting that closely related G9 strains are persistent and widespread in Asian countries.

Immunogenicity, reactogenicity and safety of a human rotavirus vaccine (RIX4414) in Korean infants: A randomized, double-blind, placebo-controlled, phase IV study

“…Jung soo Kim, 1 chong-Woo Bae, 2 Kyung-Yil Lee, 3 Moon sung park, 4 Young Youn choi, 5 Kwang-Nam Kim, 6 Jong Duck Kim,7 Won-soon park, 8 Jong-Beom sin, 9 ellen ai-Rhan Kim, 10 sang-Geel Lee, 11 chun soo Kim,12 sung-Ho cha, 13 Young Jin Hong, 14, * son-Moon shin, 15 Gyu-Hong shim, 16 Kyong Min choi,…”

“…One subject withdrew from the study due to most prevalent G types, G9 has emerged as one of the most widespread genotypes in the world, and the fifth prevailing genotype in Korea. 7,8 Vaccination appears to be the most strategic approach toward controlling and reducing RV disease burden, as improvement in sanitary conditions has minimal effect in reducing the disease burden. 9 An oral live attenuated human rotavirus vaccine, RIX4414 (Rotarix TM , GlaxoSmithKline [GSK] Biologicals) was developed from the parent vaccine strain 89-12.…”